Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped down prior to trading on Thursday . The stock had previously closed at $12.34, but opened at $11.86. Sysmex shares last traded at $11.88, with a volume of 497 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research raised Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Sysmex Trading Up 1.4%

The firm’s 50-day simple moving average is $10.33 and its 200-day simple moving average is $9.34. The firm has a market capitalization of $7.65 billion, a PE ratio of 28.95 and a beta of 1.05. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings data on Friday, August 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 7.87% and a net margin of 7.62%.The firm had revenue of $825.85 million for the quarter, compared to the consensus estimate of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Equities analysts expect that Sysmex Corporation ADR will post 0.38 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.